anti-CD5 CAR T-cell therapy (University of Pennsylvania)

N/A

Report date: 2025/01/26 18:41:09

Base Information

Drug Nameanti-CD5 CAR T-cell therapy (University of Pennsylvania)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionT-cell surface glycoprotein CD5 modulators

TargetsT-cell surface glycoprotein CD5

Therapy Area/IndicationsLymphoma, T-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Pennsylvania

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Pennsylvania

Inactive CompaniesN/A

Active IndicationsLymphoma, T-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A